Flatiron Health Presents Three Real-World Evidence Studies on NSCLC Treatment Patterns at WCLC 2026
核心洞察
Flatiron Health (搜索) announced three research acceptances at the IASLC 2026 World Conference on Lung Cancer, showcasing real-world evidence on non-small cell lung cancer (搜索) (NSCLC) treatment patterns and outcomes.
The studies examine immunotherapy use in high PD-L1 (搜索) NSCLC patients lacking approved targeted therapies, durvalumab consolidation in stage III KRAS G12C (搜索)-mutant disease, and adjuvant osimertinib in early-stage NSCLC.
The findings draw on Flatiron's Panoramic Database and unified global oncology engine, demonstrating how real-world data can guide precision medicine and treatment optimization across diverse patient populations.
Flatiron Health (搜索) has announced its presence at the IASLC 2026 World Conference on Lung Cancer (WCLC 2026), hosted by the International Association for the Study of Lung Cancer, with three research acceptances highlighting real-world evidence that advances precision medicine and treatment optimization in non-small cell lung cancer (搜索) (NSCLC). The presentations demonstrate how Flatiron's high-quality, longitudinal data reveals clinical insights that shape oncology decision-making across the globe.
"Recent advances have fundamentally transformed treatment options for lung cancers, and our research highlights where and when these novel treatments are having an impact for patients in real-world practice," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health (搜索). "Our WCLC research, spanning disease states, biomarker-defined subgroups, and treatment types, illuminates how to translate innovation into practice. By capturing this real-world complexity at scale through our Panoramic Database, we're generating the evidence needed to guide clinicians in a rapidly evolving treatment landscape—enabling them to deliver personalized medicine to any patient that is in front of them."
Flatiron's research at WCLC 2026 underscores the company's position as the gold standard in oncology intelligence, delivering trusted insights to guide the highest-stakes decisions in cancer care and drug development.
Immunotherapy in High PD-L1 NSCLC Without Approved Targeted Therapies
The first study examines genomic alterations without approved first-line targeted therapies in patients with NSCLC and PD-L1 (搜索) expression ≥50% who were treated with immunotherapy. This real-world evidence reveals treatment patterns and outcomes for patients with high PD-L1 expression who lack approved targeted therapy options, demonstrating how immunotherapy is being deployed in clinical practice and informing precision medicine strategies.
The abstract is authored by J.W. Riess, S. Viswanathan, S.K. Mhatre, S. Ding, I.K. Dhillon, S. Lambert, X. Ma, and B. Herzberg, with affiliations spanning UC Davis Comprehensive Cancer Center, Gilead Sciences, Flatiron Health (搜索), and Columbia University. The presentation is scheduled for Sunday, September 13, 2026, in the Resectable NSCLC (Stages I–III) session.
Durvalumab Consolidation in Stage III KRAS G12C-Mutant NSCLC
A second study evaluates real-world outcomes with chemoradiation and durvalumab consolidation in stage III KRAS G12C (搜索)–mutant NSCLC in the US. The research examines real-world treatment effectiveness and durability of durvalumab consolidation following chemoradiation in patients with stage III KRAS G12C-mutant disease, providing evidence on how emerging targeted approaches are translating to clinical outcomes.
Authored by D. Bruno, K. Sheffield, A. Brnabic, Q. Ma, R. Singh, K. Thoele, T. Puri, C.F. Avile, K. Schwed, M. Bye, A.M. Mehta, and M. Pesavento, the work draws on affiliations from City of Hope Cancer Center, Eli Lilly and Company, and Flatiron Health (搜索). The presentation is scheduled for Monday, September 14, 2026, in the Unresectable NSCLC (Stages I–III) session.
Adjuvant Osimertinib in Early-Stage NSCLC
The third study is a retrospective cohort analysis of real-world treatment duration and outcomes among patients with early-stage NSCLC receiving adjuvant osimertinib. The research analyzes treatment patterns, adherence, and survival outcomes in early-stage NSCLC patients receiving adjuvant osimertinib, revealing how precision medicine is reshaping the adjuvant treatment landscape.
The abstract is authored by E. Singhi, X. Ma, C. Rinaldi, L. Kovacevic, Y. Liang, D. Simmons, M. Lupicka, I. Arslan, M. Sandelin, J. Pye, and D. Nguyen, with affiliations from The University of Texas MD Anderson Cancer Center, Flatiron Health (搜索), AstraZeneca, and City of Hope. The presentation is scheduled for Tuesday, September 15, 2026.
A Unified Global Oncology Engine
These findings underscore Flatiron's ability to transform patient experiences into actionable intelligence—connecting evidence to practice and enabling clinicians and researchers to make clearer decisions that drive better outcomes. Flatiron Health (搜索) transforms cancer care and research through a unified, global oncology engine powered by expert-validated AI and deep clinical and scientific expertise, built from the experiences of millions of patients across the US, UK, Germany, and Japan. Flatiron Health is an independent affiliate of the Roche Group.